glp-1 agonists uses Receptor as Treatments for Type 2 Diabetes GLP-1 agonists approved for clinical

Yet, as oral bioavailability technology improves, most analysts anticipate an inflection by 2028 where pills erode injectable volume in mild-to-moderate obesity, while high-risk patients continue on depot biologics

doi: 10.1007/s11606-024-09076-z [DOI] [PMC free article] [PubMed] [Google Scholar] 20.Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S

In a small open-label trial of exenatide in people with clozapine-associated obesity (BMI 3045 kg/m 2 ), those on exenatide had about 10 pounds more weight loss than placebo at 24 weeks (Siskind D et al, J Psychiatr Res 2020;124:912)

Patients should contact their GP or diabetes specialist nurse if they experience unexpected changes in blood glucose control, significant gastrointestinal symptoms, or concerns about dietary modifications whilst on GLP-1 therapy

Action against misleading ads On 10 March, 2026, the DCGI issued a comprehensive advisory to all drug manufacturers ordering them to stop misleading advertisements and any promotion that could encourage people to use GLP-1 drugs without prescription